Palmitoyl-Protein Thioesterase 2 (PPT2) is a lysosomal enzyme encoded by the PPT2 gene that catalyzes the removal of long-chain fatty acids, particularly palmitate, from modified protein substrates. This enzymatic activity positions PPT2 as a critical component of lysosomal protein quality control mechanisms, where it facilitates the degradation and recycling of palmitoylated proteins that would otherwise accumulate and cause cellular dysfunction. The enzyme is particularly important in neuronal cells, where dysfunction leads to the neurodegenerative condition known as neuronal ceroid lipofuscinosis type 6 (CLN6).
| Property | Details |
|----------|---------|
| Protein Name | Palmitoyl-Protein Thioesterase 2 |
| Gene | PPT2 |
| UniProt ID | O60324 |
| Cellular Localization | Lysosomal membrane |
| Molecular Weight | ~38 kDa |
| EC Number | 3.1.2.22 |
Palmitoyl-Protein Thioesterase 2 (PPT2) is a lysosomal enzyme encoded by the PPT2 gene that catalyzes the removal of long-chain fatty acids, particularly palmitate, from modified protein substrates. This enzymatic activity positions PPT2 as a critical component of lysosomal protein quality control mechanisms, where it facilitates the degradation and recycling of palmitoylated proteins that would otherwise accumulate and cause cellular dysfunction. The enzyme is particularly important in neuronal cells, where dysfunction leads to the neurodegenerative condition known as neuronal ceroid lipofuscinosis type 6 (CLN6).
| Property | Details |
|----------|---------|
| Protein Name | Palmitoyl-Protein Thioesterase 2 |
| Gene | PPT2 |
| UniProt ID | O60324 |
| Cellular Localization | Lysosomal membrane |
| Molecular Weight | ~38 kDa |
| EC Number | 3.1.2.22 |
Palmitoyl-Protein Thioesterase 2 (PPT2) is a lysosomal enzyme that catalyzes the hydrolysis of thioester bonds in palmitoylated proteins. [@zhang2001] PPT2 is part of the acyl-protein thioesterase family and functions primarily within lysosomal compartments, where it removes long-chain fatty acids—particularly palmitate—from modified proteins. The enzyme is encoded by the PPT2 gene located on chromosome 6q22.31 and is structurally related to PPT1 (palmitoyl-protein thioesterase 1), though the two enzymes differ in their subcellular distribution and substrate preferences. [@hellsten2006] Unlike PPT1, which localizes to lysosomes but has broader activity, PPT2 shows more restricted compartmentalization and substrate specificity. [@auto_39423458] Dysfunction of PPT2 leads to accumulation of palmitoylated protein substrates within lysosomes, contributing to cellular toxicity and neuroinflammation. [@auto_38169466]
PPT2 functions as a serine hydrolase that removes palmitate and other long-chain fatty acid modifications from protein substrates through thioester bond cleavage. This depalmitoylation activity is essential for protein quality control within the lysosomal compartment. Palmitoylation is a reversible post-translational modification that regulates protein membrane association, trafficking, and function. By removing palmitate groups, PPT2 facilitates the degradation and recycling of modified proteins within lysosomes. The enzyme localizes to the lysosomal membrane through its transmembrane domains and interacts with other lysosomal proteins involved in autophagy and protein turnover. PPT2 activity is particularly important for clearing abnormal protein aggregates that accumulate during cellular stress. The enzyme demonstrates pH-dependent activity with optimal function in the acidic lysosomal environment (pH 4.5-5.0). PPT2 can depalmitoylate various substrates including membrane-associated signaling proteins and cytoskeletal components that are targeted to lysosomes for degradation.
Mutations in the PPT2 gene cause neuronal ceroid lipofuscinosis type 6 (CLN6), a lysosomal storage disorder characterized by progressive neurodegeneration, vision loss, and premature death. Loss of PPT2 function impairs the lysosomal degradation pathway, leading to accumulation of lipofuscin—an indigestible material composed of oxidized proteins, lipids, and other polymers—within neuronal and non-neuronal cells. This accumulation particularly affects the retina and cerebral cortex, explaining the visual and cognitive decline observed in affected patients. The inability to properly depalmitoylate substrate proteins prevents their degradation and recycling, causing proteotoxic stress and lysosomal dysfunction. Furthermore, impaired PPT2 activity disrupts autophagy flux, preventing efficient clearance of misfolded proteins and dysfunctional organelles. [@auto_38497492] Secondary consequences include mitochondrial dysfunction, increased oxidative stress, and activation of neuroinflammatory pathways. [@auto_36795483] PPT2 deficiency has also been implicated in age-related neurodegeneration, where reduced enzyme activity may contribute to accumulation of lipofuscin in aging neurons.
PPT2 mediates depalmitoylation through a serine hydrolase catalytic mechanism involving a conserved serine residue in the active site. The enzyme's transmembrane architecture positions its catalytic domain toward the lysosomal lumen, where substrate proteins are accessible. Mutations causing CLN6 typically result in loss-of-function through nonsense mutations, frameshift deletions, or missense mutations affecting the catalytic domain or membrane localization signals. Loss of PPT2 activity prevents the processing of polyubiquitinated proteins and causes improper lysosomal sorting of autophagy substrates. The accumulation of unprocessed, palmitoylated proteins triggers ER stress responses and activates pro-apoptotic pathways in neurons. [@auto_39862447] PPT2 deficiency also impairs the clearance of lipidated proteins involved in membrane trafficking and signal transduction, disrupting cellular homeostasis. Secondary effects include altered lysosomal calcium homeostasis and impaired interaction with other membrane-associated deubiquitinases and proteases.
PPT2 mutations cause CLN6, also termed late-infantile neuronal ceroid lipofuscinosis, with symptom onset typically between ages 5-10 years. Affected individuals show progressive cognitive decline, seizures, ataxia, and blindness due to retinal dystrophy. Research into PPT2 has implications for understanding lysosomal storage diseases and age-related neurodegeneration. Therapeutic approaches under investigation include enzyme replacement strategies, gene therapy, and small molecule activators designed to enhance residual PPT2 activity in affected patients. Understanding the molecular basis of PPT2 function may also inform broader strategies for treating neurodegenerative conditions characterized by lysosomal dysfunction and protein aggregate accumulation.